GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MeiraGTx Holdings PLC (NAS:MGTX) » Definitions » EPS (Diluted)

MeiraGTx Holdings (MeiraGTx Holdings) EPS (Diluted) : $-1.47 (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is MeiraGTx Holdings EPS (Diluted)?

MeiraGTx Holdings's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $0.42. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.47.

MeiraGTx Holdings's EPS (Basic) for the three months ended in Dec. 2023 was $0.42. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.47.

MeiraGTx Holdings's EPS without NRI for the three months ended in Dec. 2023 was $-0.45. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.31.

During the past 3 years, the average EPS without NRIGrowth Rate was -17.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 3.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, MeiraGTx Holdings's highest 3-Year average EPS without NRI Growth Rate was 26.70% per year. The lowest was -19.40% per year. And the median was -15.20% per year.


MeiraGTx Holdings EPS (Diluted) Historical Data

The historical data trend for MeiraGTx Holdings's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MeiraGTx Holdings EPS (Diluted) Chart

MeiraGTx Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial -1.65 -1.54 -1.80 -2.87 -1.49

MeiraGTx Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.58 -0.62 -0.53 -0.74 0.42

Competitive Comparison of MeiraGTx Holdings's EPS (Diluted)

For the Biotechnology subindustry, MeiraGTx Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MeiraGTx Holdings's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MeiraGTx Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where MeiraGTx Holdings's PE Ratio falls into.



MeiraGTx Holdings EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

MeiraGTx Holdings's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-84.027-0)/56.487
=-1.49

MeiraGTx Holdings's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(20.215-0)/62.312
=0.32

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MeiraGTx Holdings  (NAS:MGTX) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


MeiraGTx Holdings EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of MeiraGTx Holdings's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


MeiraGTx Holdings (MeiraGTx Holdings) Business Description

Traded in Other Exchanges
Address
450 East 29th Street, 14th Floor, New York, NY, USA, 10016
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Executives
Perceptive Life Sciences Master Fund Ltd director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Johnson & Johnson Innovation - Jjdc, Inc. 10 percent owner 410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Johnson & Johnson 10 percent owner ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933
Robert K Zeldin officer: Chief Medical Officer C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Robert J Wollin officer: General Counsel and Secretary 450 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Debra Yu director C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Alexandria Forbes director, officer: President & CEO C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Richard Giroux officer: Chief Operating Officer C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Stuart Naylor director, officer: Chief Dev. Officer C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Joel S Marcus director C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Thomas E Shenk director C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Nicole Seligman director C/O VIACOM INC., 1515 BROADWAY, NEW YORK NY 10036
Perceptive Advisors Llc director, 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Ellen Hukkelhoven director C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003

MeiraGTx Holdings (MeiraGTx Holdings) Headlines

From GuruFocus

MeiraGTx Appoints Debra Yu, MD to Board of Directors

By GuruFocusNews GuruFocusNews 04-27-2022